Characterization of COVID-19 Hospitalized Patients in Three United States Electronic Health Record Databases

Author:

Saunders-Hastings Patrick1,Zhou Cindy Ke2,Hobbi Shayan3,Boyd Eva1,Lloyd Patricia2,Alawar Nader3,Burrell Timothy3ORCID,Beers Jeff3,Clarke Tainya C.2,Hettinger Aaron Z.4ORCID,Wong Hui-Lee2,Shoaibi Azadeh2

Affiliation:

1. Gevity Consulting Inc., part of Accenture, Ottawa, ON K1P 1A4, Canada

2. Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA

3. IBM Consulting, Bethesda, MD 20814, USA

4. Center for Biostatistics, Informatics and Data Science, MedStar Health Research Institute, Hyattsville, MD 20782, USA

Abstract

COVID-19 infections have contributed to substantial increases in hospitalizations. This study describes demographics, baseline clinical characteristics and treatments, and clinical outcomes among U.S. patients admitted to hospitals with COVID-19 during the prevaccine phase of the pandemic. A total of 20,446 hospitalized patients with a positive COVID-19 nucleic acid amplification test were identified from three large electronic health record databases during 5 February–30 November 2020 (Academic Health System: n = 4504; Explorys; n = 7492; OneFlorida: n = 8450). Over 90% of patients were ≥30 years of age, with an even distribution between sexes. At least one comorbidity was recorded in 84.6–96.1% of patients; cardiovascular and respiratory conditions (28.8–50.3%) and diabetes (25.6–44.4%) were most common. Anticoagulants were the most frequently reported medications on or up to 28 days after admission (44.5–81.7%). Remdesivir was administered to 14.1–24.6% of patients and increased over time. Patients exhibited higher COVID-19 severity 14 days following admission than the 14 days prior to and on admission. The length of in-patient hospital stay ranged from a median of 4 to 6 days, and over 85% of patients were discharged alive. These results promote understanding of the clinical characteristics and hospital-resource utilization associated with hospitalized COVID-19 over time.

Funder

BEST

Publisher

MDPI AG

Subject

Infectious Diseases,Microbiology (medical),General Immunology and Microbiology,Molecular Biology,Immunology and Allergy

Reference22 articles.

1. (2023, January 06). Centers for Disease Control and Prevention COVID Data Tracker, Available online: https://covid.cdc.gov/covid-data-tracker.

2. Epidemiology, Clinical Features, and Outcomes of Hospitalized Adults with COVID-19: Early Experience from an Academic Medical Center in Mississippi;Lucar;South. Med. J.,2021

3. Clinical characteristics, multiorgan dysfunction and outcomes of patients with COVID-19: A prospective case series;Honarmand;CMAJ Open,2022

4. U.S. Food and Drug Administration, Center for Biologics Evaluation and Research (2021, June 23). COVID-19: Developing Drugs and Biological Products for Treatment or Prevention, Available online: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/covid-19-developing-drugs-and-biological-products-treatment-or-prevention.

5. Marcello, R.K., Dolle, J., Grami, S., Adule, R., Li, Z., Tatem, K., Anyaogu, C., Apfelroth, S., Ayinla, R., and Boma, N. (2020). Characteristics and Outcomes of COVID-19 Patients in New York City’s Public Hospital System. PLoS ONE, 15.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3